Quick Allison, Patel Disha, Hadziahmetovic Mersiha, Chakravarti Arnab, Mehta Minesh
Department of Radiation Oncology, Ohio State University, Madison, WI, 53792, USA.
Rev Recent Clin Trials. 2010 Jan;5(1):14-27. doi: 10.2174/157488710790820544.
Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor. Median survival rates range from 12-15 months. The current standard of care for GBM has evolved from resection followed by adjuvant radiotherapy to resection, concurrent adjuvant chemotherapy (temozolomide) and radiation, and additional adjuvant chemotherapy. The expression of specific molecular biomarkers, especially O-6-methylguanine methyltransferase (MGMT) status, may determine the response of the tumor to treatment, and helps in identifying the magnitude of benefit from this regimen. By identifying further biological subtypes of GBM at the molecular level, specific targeted therapies could be developed and used in the future for more individualized therapeutic regimens. This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents.
胶质母细胞瘤（GBM）是世界卫生组织IV级恶性胶质瘤，是最常见且致命的成人原发性脑肿瘤。中位生存期为12至15个月。目前GBM的标准治疗方法已从手术切除后辅助放疗发展为手术切除、同步辅助化疗（替莫唑胺）和放疗，以及额外的辅助化疗。特定分子生物标志物的表达，尤其是O-6-甲基鸟嘌呤甲基转移酶（MGMT）状态，可能决定肿瘤对治疗的反应，并有助于确定该治疗方案的获益程度。通过在分子水平识别GBM的更多生物学亚型，未来可以开发并使用特定的靶向治疗方法，用于更个体化的治疗方案。本文将综述GBM的当前治疗方法以及新分子和靶向治疗的研究，如表皮生长因子受体（EGFR）抑制剂、雷帕霉素靶蛋白/磷脂酰肌醇-3激酶（mTOR/PI3Kinase）抑制剂和抗血管生成药物。
